[go: up one dir, main page]

ZA984211B - Glucosamine fatty acids - Google Patents

Glucosamine fatty acids

Info

Publication number
ZA984211B
ZA984211B ZA984211A ZA984211A ZA984211B ZA 984211 B ZA984211 B ZA 984211B ZA 984211 A ZA984211 A ZA 984211A ZA 984211 A ZA984211 A ZA 984211A ZA 984211 B ZA984211 B ZA 984211B
Authority
ZA
South Africa
Prior art keywords
fatty acids
glucosamine fatty
glucosamine
acids
fatty
Prior art date
Application number
ZA984211A
Inventor
David Frederick Horrobin
Mehar Singh Manku
Austin Mc Mordie
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of ZA984211B publication Critical patent/ZA984211B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA984211A 1997-05-20 1998-05-19 Glucosamine fatty acids ZA984211B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9710351.9A GB9710351D0 (en) 1997-05-20 1997-05-20 Glucosamine fatty acids

Publications (1)

Publication Number Publication Date
ZA984211B true ZA984211B (en) 1998-11-20

Family

ID=10812725

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA984211A ZA984211B (en) 1997-05-20 1998-05-19 Glucosamine fatty acids

Country Status (6)

Country Link
EP (1) EP0977561A1 (en)
AU (1) AU7442398A (en)
CA (1) CA2290488A1 (en)
GB (1) GB9710351D0 (en)
WO (1) WO1998052556A1 (en)
ZA (1) ZA984211B (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214666B1 (en) 1999-11-02 2007-05-08 Shawn Paul Madere Composition of orally administered nutritional supplements to repair articular cartilage
WO2001032188A1 (en) * 1999-11-02 2001-05-10 Shawn Paul Madere Compositions of orally administered nutritional supplements to repair articular cartilage
DE10019255A1 (en) * 2000-04-18 2001-10-31 Henkel Kgaa Glycoside esters and their production and use in cosmetics, pharmaceuticals and food or feed
CN100582085C (en) * 2002-10-10 2010-01-20 耶达研究及发展有限公司 Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
US20070213298A1 (en) * 2006-02-07 2007-09-13 Universitetet I Oslo Omega 3
DE102007055344A1 (en) 2007-11-19 2009-05-20 K. D. Pharma Bexbach Gmbh New use of omega-3 fatty acid (s)
FR2940281B1 (en) * 2008-12-22 2011-04-01 Fabre Pierre Dermo Cosmetique ESTER OF DIOL AND POLYUNSATURATED FATTY ACID AS ANTI-ACNE AGENT
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
AU2011349718B2 (en) * 2010-12-21 2017-02-09 Nestec S.A. Methods and compositions for preventing and treating osteoarthritis
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
EP2847169A4 (en) 2012-05-07 2015-09-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168003A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammation
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
EP2852570B1 (en) 2012-05-23 2020-04-22 Cellixbio Private Limited Composition for the treatment of inflammatory bowel disease
CA2873104A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
MA52644A (en) 2014-06-04 2021-03-24 Ds Biopharma Ltd PHARMACEUTICAL COMPOSITIONS CONSISTING OF DGLA ACID AND THEIR USE
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (en) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 Composition and method for treating multiple sclerosis
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
JP6679616B2 (en) 2015-01-06 2020-04-22 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ Compositions and methods for the treatment of inflammation and pain
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939813A (en) * 1982-08-26 1984-03-05 Shiseido Co Ltd Cosmetic
EP0650492A1 (en) * 1992-05-26 1995-05-03 Alberta Research Council Reducing inflammation by time dependent administration of oligosaccharides glycosides related to blood group determinants
GB9413935D0 (en) * 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer
GB9508023D0 (en) * 1995-04-20 1995-06-07 Scotia Holdings Plc Fatty acid derivatives
AU2623797A (en) * 1995-12-11 1997-07-03 Inholtra, Inc. Dietary regimen of nutritional supplements for relief of symptoms of arthritis

Also Published As

Publication number Publication date
AU7442398A (en) 1998-12-11
GB9710351D0 (en) 1997-07-16
CA2290488A1 (en) 1998-11-26
WO1998052556A1 (en) 1998-11-26
EP0977561A1 (en) 2000-02-09

Similar Documents

Publication Publication Date Title
GB9710351D0 (en) Glucosamine fatty acids
HU9801045D0 (en) Substituted diamino-carboxylic acids
PL348244A1 (en) Substituted indolealkanoic acids
ZA951661B (en) Fatty acid derivatives
AU6482398A (en) Sulfonylaminocarboxylic acids
AU5470299A (en) Fatty ester combinations
TW371531U (en) High speed connector
HUP0000937A3 (en) New fatty acid derivatives
GB2328251B (en) Propeller
EP0801644A4 (en) Polyarylcarbamoylaza -and- carbamoylalkanedioic acids
GB9508023D0 (en) Fatty acid derivatives
ZA952008B (en) 5-vinyl- and 5-ethinyl-quinolene- and -naphthyridone- carboxylic acids
GB9706281D0 (en) Ester co-production
PL332553A1 (en) 3-alkooxyisooxazol-4-yl-substituted 2-aminocarboxylic acids
GB9420010D0 (en) Nucleic acids
GB9812674D0 (en) Nucleic acids
IL129500A0 (en) Fatty acid derivatives II
GB2333525B (en) Esterification process
HUP9901345A3 (en) Novel quinoxaline- and quinoxalinylalkane-phosphonic acids
GB9408064D0 (en) Nucleic acids
GB9700383D0 (en) Fatty acid treatent
AU8018498A (en) Oligomers of fatty acids
ZA977376B (en) Propeller
GB9702004D0 (en) Esterification process
AU3645195A (en) Modified polyunsaturated fatty acids